Patient Derived Xenograft Model Market to See Booming Growth 2023-2030 | Horizon Discovery Ltd., Oncodesign, Pharmatest Services, Shanghai LIDE Biotech

According to Coherent Market Insights, The Patient Derived Xenograft Model Market size is expected to reach US$ 346 million by 2030, from US$ 105.4 million in 2023, at a CAGR of 18.5% during the forecast period.

Market Overview:

Patient derived xenograft (PDX) models use tumor tissue that is directly implanted from a patient into animals, typically immunodeficient mice. These models help understand disease progression and evaluate therapeutic responses in a manner that is more clinically relevant and predictive of human tumors than conventional cancer cell lines.

Market Dynamics:

The patient derived xenograft model market is witnessing significant growth due to increasing prevalence of cancer worldwide. It is estimated that in 2023, approximately 18 million new cancer cases and 10 million cancer deaths will occur. PDX models closely recapitulate original patient tumors and enable longitudinal studies of tumor growth and diversity in treatment responses. They have the potential to facilitate rapid personalized medicine approaches and predictive drug discovery. Furthermore, increasing funding for cancer research from government and private institutions is also fueling the market growth.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/6506

Opportunity:Growing PDX Model Outsourcing to Specialized Service Providers

The complexity and expenses associated with developing and maintaining in-house PDX programs is creating opportunities for outsourcing to specialized service providers. A growing number of PDX providers offer services for tumor grafting, expansion, cryopreservation, histological and molecular annotation as well as custom model development. Companies provide ready access to thousands of well-characterized models through fee-for-service arrangements or collaborative agreements. This outsourcing model helps address the cost barrier and allows research organizations to leverage clinically relevant models without investing heavily in infrastructure and expert personnel. It also provides access to wider varieties of cancer types. As such, the outsourcing approach is gaining popularity as it provides efficiencies of scale and flexibility to address specific research needs. The evolving demand is encouraging new entrants offering scalable PDX services. This opportunity for increased outsourcing to specialized service providers is expected to accelerate commercialization of PDX technologies.

Competitive Landscape

In the segment specifically devoted to leading companies in the Patient Derived Xenograft Model Market of the market analysis document, our researchers provide a summary of the financial statements of all the major companies, covering their noteworthy developments, product benchmarking, and SWOT analysis. The corporate profile copy also includes financial information and a business summary. The businesses in this area can be customized to match the unique needs of the client.

Some of the Top Players in Patient Derived Xenograft Model Market:

THE JACKSON LABORATORY, Champions Oncology, Inc, Charles River Laboratories, Crown Bioscience, Hera Biolabs, Horizon Discovery Ltd., Oncodesign, Pharmatest Services, Shanghai LIDE Biotech, Aragen Life Sciences Ltd., Creative Animodel, Urosphere, Applied StemCell and WuXi AppTec

Patient Derived Xenograft Model Market Segmentation:

By Model Type
Tumor explant models
Cell line derived models
Patient derived organoids
Genetically engineered models
Others (Primary cell derived models, cell processed models etc.)

By Implantation Method
Subcutaneous Implantation
Orthopedic Implantation
Others

By Tumor Type
Gastrointestinal Tumor Model
Gynecological Tumor Model
Respiratory Tumor Model
Other Tumor Model

By End User
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Research Institutions
Others

Regional Analysis -

North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
Latin America (Colombia, Brazil, Argentina, Rest of Latin America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now and Get a Discount on this Report @ https://www.coherentmarketinsights.com/insight/buy-now/6506

Driver: Growing Focus on Personalized Medicine and Translational Research is Fueling Demand for PDX Models

The growing focus on personalized medicine and translational research has been a major driver of growth in the PDX model market. PDX models enable researchers to study how tumors grow and respond to different therapies in an environment much closer to human tumors than traditional models. This provides insights to help advance the development of personalized cancer treatments tailored to individual patients. As understanding of molecular subtypes of cancer increases, the need for disease-relevant preclinical tools to evaluate new targeted therapies is escalating. Compared to cell lines, PDX models better preserve intratumoral heterogeneity and the molecular characteristics of the original patient tumors. Their ability to more accurately recapitulate human cancer biology and predict therapeutic responses makes them an invaluable tool for developing personalized treatments and precision medicines. With growing emphasis on precision medicine approaches in oncology, demand for PDX models that can aid such research efforts is expected to steadily rise.

Driver: Increasing Adoption of Patient-Derived Xenograft Technology by Pharmaceutical Companies

Pharmaceutical and biotech companies are increasingly adopting PDX technology to advance their drug development pipelines. PDX models offer advantages over traditional cell line-based models as they aid in identifying effective therapeutic targets and biomarkers, evaluating novel compounds, conducting target validation studies, and assessing combination therapies. Many big pharmaceutical players are establishing PDX biobanks and collaborating with PDX providers to incorporate these models early in the development process. This helps streamline target evaluations, drug screening, and other preclinical studies in a more predictive human tumor environment. The capability of PDX models to aid compound screening and patient selection for clinical trials is encouraging more investment from industry players. Additionally, growing awareness of limitations of traditional preclinical tools is further elevating investment in PDX technologies by biopharma companies seeking improved translational power. This rising adoption is cementing the position of PDX models in oncology drug development and driving significant market opportunities.

Restrain: High Cost of Establishing and Maintaining PDX Models

One of the key restrains hampering greater adoption of PDX models is the high costs associated with establishing and maintaining these models. Developing a PDX model from a patient tumor biopsy requires specialized expertise and infrastructure for propagation, characterization, and cryopreservation. Further, long-term maintenance of PDX facilities involves substantial financial investment for housing immunodeficient rodents, employ trained technicians, perform serial passaging, histopathological and molecular evaluations, etc. Overall operational expenses can run into hundreds of thousands of dollars annually. This economic barrier restricts access of these clinically relevant models especially for small biotech companies and academic labs with limited budgets. High licensing fees for commercially available PDX models add to the costs. While their strengths are attracting big pharma, cost remains a major consideration for wider utilization of PDX technologies especially in the initial stages of research. This financial restraint needs to be addressed to realize full potential of PDX models in translational science.

Reasons to Purchase this Report:

✔ Regional report analysis highlighting the consumption of products/services in a region also shows the factors that influence the market in each region.
✔ Reports provide opportunities and threats faced by suppliers in the Patient Derived Xenograft Model industry around the world.
✔ The report shows regions and sectors with the fastest growth potential.
✔A competitive environment that includes market rankings of major companies, along with new product launches, partnerships, business expansions, and acquisitions.
✔ The report provides an extensive corporate profile consisting of company overviews, company insights, product benchmarks, and SWOT analysis for key market participants.
✔ This report provides the industry's current and future market outlook on the recent development, growth opportunities, drivers, challenges, and two regional constraints emerging in advanced regions.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/6506

Questions Answered by the Report:

(1) Which are the dominant players of the Patient Derived Xenograft Model Market?
(2) What will be the size of the Patient Derived Xenograft Model Market in the coming years?
(3) Which segment will lead the Patient Derived Xenograft Model Market?
(4) How will the market development trends change in the next five years?
(5) What is the nature of the competitive landscape of the Patient Derived Xenograft Model Market?
(6) What are the go-to strategies adopted in the Patient Derived Xenograft Model Market?

Table of Contents

Chapter 1 Market Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Market Size Analysis from 2023 to 2030

Chapter 2 Competition by Types, Applications, and Top Regions and Countries
2.1 Market (Volume and Value) by Type
2.3 Market (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Worldwide Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Patient Derived Xenograft Model Sales, Consumption, Export, Import by Regions (2023-2023)
Chapter 5 North America Market Analysis
Chapter 6 Europe Market Analysis
Chapter 7 Middle East and Africa Market Analysis
Chapter 8 Asia Pacific Market Analysis
Chapter 9 Latin America Market Analysis
Chapter 10 Company Profiles and Key Figures in Patient Derived Xenograft Model Business
Chapter 11 Market Forecast (2023-2030)
Chapter 12 Conclusions

533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States📌Contact Us:
Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
📞U.K.: +44-020-8133-4027
📞JAPAN: +81-50-5539-1737
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.